SELLAS Life Sciences Group, Inc. (SLS) Key Metrics
SLS valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.02B
- Enterprise value
- $2.18B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 26.9
- Price / book
- 16.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.57
SLS key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSLS valuation Price multiples at each fiscal year-end price.
SLS returns How much profit the business earns on the capital it uses.
SLS per-share figures Results divided by the shares outstanding at year-end.
SLS financial health Debt, liquidity and how easily interest is covered.
SLS valuation history
SLS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SLS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SLS cash returned to shareholders
SLS price vs earnings per share
SLS key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $411.1M | $63.7M | — | — | — | — | — | — | — | — |
| Enterprise value | $340.2M | $50.8M | — | — | — | — | — | — | — | — |
| Price / book | 5.8 | 6.7 | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | 80.3 | — | — | — | — | — | — | — | — |
| Earnings yield | −6.5% | −48.5% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −6.9% | −55.6% | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $3.77 | $1.04 | $1.06 | $2.36 | $5.53 | $5.81 | $4.30 | $61.50 | $393.00 | $2,910.00 |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Earnings per share | −$0.25 | −$0.50 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.26 | −$0.58 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$0.26 | −$0.58 | — | — | — | — | — | — | — | — |
| Cash per share | $0.66 | $0.23 | — | — | — | — | — | — | — | — |
| Book value per share | $0.65 | $0.15 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $0.63 | $0.12 | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Debt per share | $0.01 | $0.02 | — | — | — | — | — | — | — | — |
| Shares outstanding | 109.1M | 61.2M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +78.2% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −66.9% | — | — | −327.8% | −85.7% | −98.4% | −340.3% | −756.5% | −154.6% | −111.7% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | — | — | −57.2% | −119.4% |
| Return on assets (ROA) | −54.9% | −240.8% | −274.9% | −174.4% | −57.1% | −53.5% | −115.1% | −109.7% | −47.8% | −31.8% |
| Return on tangible assets | −35.1% | −176.3% | −867.4% | −217.0% | −84.4% | −43.6% | −214.5% | −425.6% | −169.5% | −62.3% |
| Free cash flow margin | — | — | — | — | −342.4% | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.0M | $1.0M | $906,000 | $945,000 | $808,000 | $991,000 | $217,000 | — | $11.0M | $22.1M |
| Cash & short-term investments | $71.9M | $13.9M | $2.5M | $17.1M | $21.5M | $35.3M | $7.3M | $5.3M | $2.3M | $18.1M |
| Net debt | −$70.9M | −$12.9M | −$1.6M | −$16.2M | −$20.6M | −$34.3M | −$7.1M | −$5.3M | $8.7M | $4.0M |
| Debt / equity | 0.01 | 0.11 | — | 0.19 | 0.04 | 0.04 | 0.04 | — | 5.31 | 0.77 |
| Debt / assets | 0.01 | 0.05 | 0.15 | 0.05 | 0.03 | 0.02 | 0.01 | — | 0.33 | 0.34 |
| Net debt / EBITDA | — | −20.39 | −3.07 | — | — | −1.29 | −10.57 | — | — | — |
| Current ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 | 2.99 | 1.56 | 0.98 | 0.53 | 1.23 |
| Quick ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 | 2.96 | 1.45 | 0.98 | 0.53 | 1.23 |
| Interest coverage | — | — | — | -64.6 | -5.8 | -43.5 | -169.8 | -118.8 | -34.0 | -4.6 |
| Working capital | $68.2M | $6.8M | −$10.6M | $2.2M | $18.1M | $24.6M | $3.0M | −$136,000 | −$11.5M | $7.1M |
| Invested capital | −$21,000 | −$3.4M | −$9.6M | −$11.3M | −$300,000 | −$6.3M | −$967,000 | −$92,000 | $10.7M | $32.6M |
| Tangible asset value | $69.0M | $7.6M | −$9.9M | $2.9M | $18.4M | $20.3M | −$1.5M | −$5.2M | −$17.4M | $640,000 |
| Net current asset value | $67.7M | $6.4M | −$11.0M | $1.7M | $17.0M | $18.8M | −$2.3M | −$5.8M | −$18.4M | $345,000 |
| Graham net-net per share | $0.59 | $0.06 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | $0 | $487,000 | $675,000 | $487,000 |
| Share buybacks (net) | — | — | $31,000 | — | — | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | — | — | — | 450.0% | 0.0% | 0.0% | — | — | — | — |
| Capex / depreciation | — | 0.00 | 0.15 | 9.85 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 |
| Stock-based compensation / revenue | — | — | — | 172.6% | 13.3% | 30,421.1% | — | — | — | — |
| R&D / revenue | — | — | — | 3,026.8% | 281.2% | 488,526.3% | — | — | — | — |
| SG&A / revenue | — | — | — | 1,258.2% | 148.9% | 505,263.2% | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | 137,931.6 | — | — | — | — |
| Days of inventory on hand | — | — | — | — | — | 502.5 | — | — | — | — |
| Days payables outstanding | — | — | — | 10,039.3 | 6,205.9 | 4,143.3 | — | — | — | 148,250.8 |
| Cash conversion cycle (days) | — | — | — | — | — | 134,290.8 | — | — | — | — |
| Receivables turnover | — | — | — | — | — | 0.00 | 0.00 | — | — | — |
| Payables turnover | — | — | 0.00 | 0.04 | 0.06 | 0.09 | — | 0.00 | 0.00 | 0.00 |
| Inventory turnover | — | — | — | — | — | 0.73 | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.04 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | — | $718,000 | $308,000 | — | — | — |
| Average payables | $3.2M | $4.6M | $4.5M | $2.8M | $3.4M | $4.3M | $3.8M | $7.7M | $6.3M | $1.2M |
| Average inventory | — | — | — | — | — | $519,000 | $573,000 | — | $0 | −$9.8M |
| Intangibles / total assets | 2.4% | 9.8% | 30.8% | 9.1% | 7.2% | 16.5% | 45.8% | 61.6% | 58.2% | 42.6% |
Computed from SLS's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SLS valuation and financial ratios
SELLAS Life Sciences earned a return on equity of −66.9% in fiscal 2025. It ended the year with $1.0 million of debt and $71.9 million in cash and short-term investments, a net cash position of $70.9 million.
See the SLS income statement, the SLS chart for price history, or the SLS stock overview for the latest quote and news.
SLS key metrics FAQ
What is SELLAS Life Sciences's return on equity?
SELLAS Life Sciences's return on equity (ROE) was −66.9% in fiscal 2025: net income of -$26.9 million on average shareholders' equity of $40.2 million.
How much debt does SELLAS Life Sciences have?
SELLAS Life Sciences had total debt of $1.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is SELLAS Life Sciences's free cash flow yield?
SELLAS Life Sciences generated -$28.4 million of free cash flow in fiscal 2025, a free cash flow yield of −6.9% on its market value at year-end ($411.1 million).
What is SELLAS Life Sciences's current ratio?
SELLAS Life Sciences's current ratio was 10.72 at the end of fiscal 2025: current assets were 10.72 times current liabilities.